Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

References

• de KorteJMombersFMCBosJDSprangersMAGQuality of life in patients with psoriasis: a systematic literature reviewJ Investig Dermatol Symp Proc200492140147
   PubMed Web of Science ®Google Scholar
• SwHHoltEWHusniMEQureshiAAWillingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot studySemin Arthritis Rheum201039538439719095293
   PubMed Web of Science ®Google Scholar
• HustedJAThavaneswaranAChandranVGladmanDDIncremental effects of comorbidity on quality of life in patients with psoriatic arthritisJ Rheumatol20134081349135623772076
   PubMed Web of Science ®Google Scholar
• GratacósJDaudénEGómez-ReinoJMorenoJCCasado MiguelÁngelRodríguez-ValverdeVHealth-related quality of life in psoriatic arthritis patients in SpainReumatol Clín2014101253124099960
   PubMedGoogle Scholar
• BoehnckeW-HSchönMPPsoriasisLancet2015386999798399426025581
   PubMed Web of Science ®Google Scholar
• GargNvan den BoschFDeodharAThe concept of spondyloarthritis: Where are we now?Best Pract Res Clin Rheumatol201428566367225488776
   PubMed Web of Science ®Google Scholar
• HuscherDMerkesdalSThieleKCost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in GermanyAnn Rheum Dis20066591175118316540552
   PubMed Web of Science ®Google Scholar
• FrankeLCAmentAJvan de LaarMABoonenASeverensJLCost-of-illness of rheumatoid arthritis and ankylosing spondylitisClin Exp Rheumatol2009274 Suppl 55S11812319822057
   PubMed Web of Science ®Google Scholar
• ParisiRSymmonsDPMGriffithsCEMAshcroftDMGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol2013133237738523014338
   PubMed Web of Science ®Google Scholar
• GudjonssonJEJohnstonASigmundsdottirHValdimarssonHImmunopathogenic mechanisms in psoriasisClin Exp Immunol200413511814678257
   PubMed Web of Science ®Google Scholar
• FarleyEMenterAPsoriasis: comorbidities and associationsG Ital Dermatol Venereol2011146191521317853
   PubMed Web of Science ®Google Scholar
• MeasePJArmstrongAWManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisDrugs201474442344124566842
   PubMed Web of Science ®Google Scholar
• SalvadoriniGBandinelliFdelle SedieAAnkylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decadesClin Exp Rheumatol201230456156522510360
   PubMed Web of Science ®Google Scholar
• RudwaleitMHaibelHBaraliakosXThe early disease stage in axial spondylarthritis: Results from the German spondyloarthritis inception cohortArthritis Rheumatol2009603717727
   PubMed Web of Science ®Google Scholar
• SchettGLoriesRJD’AgostinoM-AEnthesitis: from pathophysiology to treatmentNat Rev Rheumatol2017131273174129158573
   PubMed Web of Science ®Google Scholar
• ZengQChenRDarmawanJRheumatic diseases in ChinaArthritis Res Ther2008101R1718237382
   PubMed Web of Science ®Google Scholar
• HoffMGulatiAMRomundstadPRKavanaughAHaugebergGPrevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag Health Study (HUNT)Ann Rheum Dis2015741606423962458
   PubMed Web of Science ®Google Scholar
• AkkocNAre spondyloarthropathies as common as rheumatoid arthritis worldwide? A reviewCurr Rheumatol Rep200810537137818817640
   PubMedGoogle Scholar
• HazardECherrySBLallaDWoolleyJMWilfehrtHChiouCFClinical and economic burden of psoriasisManag Care Interface20061942026
   PubMedGoogle Scholar
• MdefspdeOliveiraBdeoRochaDuarteGVPsoriasis: classical and emerging comorbiditiesAn Bras Dermatol201590192025672294
   PubMed Web of Science ®Google Scholar
• GhatnekarOLjungbergAWirestrandLESvenssonACosts and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional studyEur J Dermatol201222223824522361745
   PubMed Web of Science ®Google Scholar
• BergerKEhlkenBKuglandBAugustinMCost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in GermanyJ Dtsch Dermatol Ges20053751151815967010
   PubMedGoogle Scholar
• LevyARDavieAMBrazierNCEconomic burden of moderate to severe plaque psoriasis in CanadaInt J Dermatol201251121432144023171010
   PubMed Web of Science ®Google Scholar
• PooleCDLebmeierMAraRRafiaRCurrieCJEstimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UKRheumatology201049101949195620581376
   PubMed Web of Science ®Google Scholar
• BoonenADirect costs of ankylosing spondylitis and its determinants: an analysis among three European countriesAnn Rheum Dis200362873274012860728
   PubMed Web of Science ®Google Scholar
• KobeltGAndlin-SobockiPMaksymowychWPCosts and quality of life of patients with ankylosing spondylitis in CanadaJ Rheumatol200633228929516465660
   PubMed Web of Science ®Google Scholar
• ColomboGModerate and severe plaque psoriasis: cost-of-illness study in ItalyTher Clin Risk Manag20084255956818728854
   PubMedGoogle Scholar
• OlivieriIde PortuSSalvaraniCThe psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapyRheumatology200847111664167018725374
   PubMed Web of Science ®Google Scholar
• ConaghanPAltenRStrandVThe relationship between physical functioning and work for people with psoriatic arthritis: results from a large real-world study in 16 countries [Abstract 1712]Arthritis Rheumatol201668Suppl 10
   Google Scholar
• CortesiPAScaloneLD’AngiolellaLSystematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritisClin Exp Rheumatol2012304 Suppl 73S12613123072771
   PubMed Web of Science ®Google Scholar
• AltobelliEMaccaroneMPetrocelliRAnalysis of health care and actual needs of patients with psoriasis: a survey on the Italian populationBMC Public Health2007715917448249
   PubMed Web of Science ®Google Scholar
• Burgos-PolRMartínez-SesmeroJMVentura-CerdáJMElíasICalotoMTCasadoMÁ. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic reviewActas Dermosifiliogr2016107757759027316590
   PubMed Web of Science ®Google Scholar
• WilliamsEMWalkerRJFaithTEgedeLEThe impact of arthritis and joint pain on individual healthcare expenditures: findings from the Medical Expenditure Panel Survey (MEPS), 2011Arthritis Res Ther20171913828245879
   PubMed Web of Science ®Google Scholar
• RamondaRMarchesoniACarlettoAPatient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS surveyArthritis Res Ther20161817827037139
   PubMed Web of Science ®Google Scholar
• SmolenJSSchölsMBraunJTreating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task forceAnn Rheum Dis201877131728684559
   PubMed Web of Science ®Google Scholar
• AvedeCarvalhoRomitiRCdasSouzaPsoriasis comorbidities: complications and benefits of immunobiological treatmentAn Bras Dermatol201691678178928099601
   PubMed Web of Science ®Google Scholar
• MrowietzUImplementing treatment goals for successful long-term management of psoriasisJ Eur Acad Dermatol Venereol201226Suppl 3122022356631
   PubMed Web of Science ®Google Scholar
• NorlinJMSteen CarlssonKPerssonUSchmitt-EgenolfMSwitch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practiceDermatology2012225432633223328678
   PubMed Web of Science ®Google Scholar
• SmithCHJabbar-LopezZKYiuZZBritish Association of Dermatologists guidelines for biologic therapy for psoriasis 2017Br J Dermatol2017177362863628513835
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughAMeasePJGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritisArthritis Rheumatol20166851060107126749174
   PubMed Web of Science ®Google Scholar
• WardMMDeodharAAklEAAmerican College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritisArthritis Rheumatol201668228229826401991
   PubMed Web of Science ®Google Scholar
• van der HeijdeDRamiroSLandewéR2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritisAnn Rheum Dis201776697899128087505
   PubMed Web of Science ®Google Scholar
• Cosentyx Summary of Product Characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003729/WC500183132.pdfAccessed March 25, 2018
   Google Scholar
• Taltz – update from EMA regarding adoptation of new indication for Taltz2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003729/WC500183132.pdfAccessed March 25, 2018
   Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two Phase 3 trialsN Engl J Med Overseas Ed20143714326338
   PubMed Web of Science ®Google Scholar
• MeasePJMcinnesIBKirkhamBSecukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisN Engl J Med Overseas Ed20153731413291339
   PubMed Web of Science ®Google Scholar
• BaetenDSieperJBraunJSecukinumab, an interleukin-17A inhibitor, in ankylosing spondylitisN Engl J Med Overseas Ed20153732625342548
   PubMed Web of Science ®Google Scholar
• ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol201573340040926092291
   PubMed Web of Science ®Google Scholar
• StrandVMeasePGossecLSecukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised Phase III trial (FUTURE 1)Ann Rheum Dis201776120320727169431
   PubMed Web of Science ®Google Scholar
• McinnesIBMeasePJKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, Phase 3 trialLancet201538699991137114626135703
   PubMed Web of Science ®Google Scholar
• McinnesIBMeasePJRitchlinCTSecukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the Phase 3 FUTURE 2 studyRheumatology201756111993200328968735
   PubMed Web of Science ®Google Scholar
• DeodharAADougadosMBaetenDLEffect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a Phase III randomized trial (MEASURE 1)Arthritis Rheumatol201668122901291027390130
   PubMed Web of Science ®Google Scholar
• SieperJDeodharAMarzo-OrtegaHSecukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 studyAnn Rheum Dis201776357159227582421
   PubMed Web of Science ®Google Scholar
• PuigLNotarioJJiménez-MoralesASecukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health ServiceJ Dermatolog Treat201728762363028784002
   PubMed Web of Science ®Google Scholar
• GoereeRChiva-RazaviSGundaPCost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspectiveJ Med Econ201821216317328945143
   PubMed Web of Science ®Google Scholar
• D’AusilioAAielloADanielFGrahamCRocciaAToumiMA cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in ItalyValue Health2015187A424
   Web of Science ®Google Scholar
• LeeAGregoryVGuQBeckerDLBarbeauMCost-effectiveness of secukinumab compared to current treatments for the treatment of moderate to severe plaque psoriasis in CanadaValue Health2015183A182
   Web of Science ®Google Scholar
• Costa-ScharplatzMLangAGustavssonAFasthACost-effectiveness of secukinumab compared to ustekinumab in patients with psoriasis from a Swedish health care perspectiveValue Health2015187A422
   Web of Science ®Google Scholar
• MauskopfJASullivanSDAnnemansLPrinciples of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysisValue Health200710533634717888098
   PubMed Web of Science ®Google Scholar
• SullivanSDMauskopfJAAugustovskiFBudget impact analysis – principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue Health201417151424438712
   PubMed Web of Science ®Google Scholar
• IMS Health Data ProcessingNovartis2016
   Google Scholar
• FavalliEGMarchesoniAColomboGLSinigagliaLPattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in ItalyClin Exp Rheumatol2008261455118328146
   PubMed Web of Science ®Google Scholar
• De CompadriPKolevaDI costi della psoriasis vulgaris nei pazienti sottoposti a terapia sistemica: una rassegna della letteratura e una stima preliminare di costo in Italia [The costs of psoriasis vulgaris in patients receiving systemic therapy: a review of the literature and a preliminary cost estimate in Italy]Quaderni di farmaco economia20086715
   Google Scholar
• Ministry of Health Tariffs of acute hospital care services [DRG tariffs]Official Journal of the Italian Republic. Series N.23; Supplement 8 of 28 January 2013 Available from: http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=1349&area=ricoveriOspedalieri&menu=sistemaAccessed March 25, 2018
   Google Scholar
• NashPMcinnesIMeasePSecukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus adalimumab using a matching-adjusted indirect comparisonArthritis Rheumatol201668Suppl 10
   Google Scholar
• McinnesIBNashPRitchlinCTHU0437 secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus licensed biologics and apremilast from a network meta-analysisAnn Rheum Dis201675Suppl 234834925433020
   PubMed Web of Science ®Google Scholar
• HaweEVickersADMallyaUGMcBrideDWCapkun-NiggliGOlsonMSecukinumab 300 mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparisonPaper presented as a poster at the 23rd European Academy of Dermatology and Venereology CongressOctoberAmsterdam, the Netherlands2014
   Google Scholar
• BaetenDMeasePStrandVSAT0390 secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus currently licensed biologics from a network meta-analysisAnn Rheum Dis201675Suppl 2809810
   Web of Science ®Google Scholar
• DuteilERachdiLCariouCBudget impact analysis of secukinumab in moderate to severe plaque psoriaris, ankylosing spondylitis and psoriatic arthritis In FranceValue in Health2016197A458
   Web of Science ®Google Scholar
• HallidayAHackingVJuglSMBudget impact of secukinumab for ankylosing spondylitis in the UKValue in Health2016197A535
   Web of Science ®Google Scholar
• Italian Republic Official Gazette Available from: http://www.gazzettauf-ficiale.it/ricerca/atto/serie_generale/originario?reset=true&normativi=falseAccessed March 25, 2018
   Google Scholar
• SaracenoRMannheimerRChimentiSRegional distribution of psoriasis in ItalyJ Eur Acad Dermatol Venereol200822332432918269600
   PubMed Web of Science ®Google Scholar
• KhalidJMGlobeGFoxKMChauDMaguireAChiouC-FTreatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort studyBMC Dermatol2013131923957883
   PubMedGoogle Scholar
• de AngelisRSalaffiFGrassiWPrevalence of spondyloarthropathies in an Italian population sample: a regional community-based studyScand J Rheumatol2007361142117454930
   PubMed Web of Science ®Google Scholar